This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: We performed a prospective study of amyotrophic lateral sclerosis (ALS) in North Canterbury, New Zealand, from 1985 to 2006, to ascertain the incidence of ALS over that 22-year period, and to detect patterns of change in incidence. We also aimed to identify factors that influenced survival.
Methods: A prospective database of all patients seen at the Department of Neurology at Christchurch Public Hospital formed the basis of this study. Additional cases were identified through hospital coding data and from neurologists’ private practice records. Kaplan-Meier life table analysis and Cox proportional hazards analyses were used for the survival analysis. Poisson regression and capture-recapture techniques were used to analyze incidence data.
Results: ALS incidence rates steadily increased by 3% per year over the 22 years, from 1.6 to 3.3 per 100,000 per year. Older age, bulbar symptoms, and male sex adversely affected survival. The median survival from diagnosis was 17.6 months and from symptom onset 27.6 months. Contemporary supportive therapies such as noninvasive ventilation and percutaneous endoscopic gastrostomy did not extend survival. There was no disease clustering and no clues to etiology were revealed.
Conclusions: We report the highest recorded incidence of amyotrophic lateral sclerosis (ALS) to date, with the incidence of ALS in Canterbury increasing over the 22 years of the study. We were unable to confirm improvement in survival using contemporary supportive therapies and confirmed older age, male sex, and bulbar onset as adverse prognostic factors. The increasing incidence is not explained by aging of the population.
GLOSSARY: ALS = amyotrophic lateral sclerosis; CDHB = Canterbury District Health Board; CPH = Christchurch Public Hospital; EEC = El Escorial criteria; ICD = International Classification of Diseases; KM = Kaplan-Meier; MND = motor neuron diseases; NDD = neurology department database; NIV = noninvasive ventilation; PMA = progressive muscle atrophy; UMN = upper motor neuron.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
